Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biotech company with a mission to deliver transformative ADCs to patients with cancer. Its core strategy is built on two proprietary technology platforms: Dolasynthen for creating homogeneous, cytotoxic ADCs and Immunosynthen for developing STING-agonist ADCs that engage the innate immune system. The company's most significant achievement is advancing its lead Dolasynthen candidate, UpRi, into a pivotal study for ovarian cancer, while also progressing earlier-stage clinical and preclinical assets. Mersana executes this strategy through internal R&D and strategic collaborations with larger pharmaceutical partners.

Mersana's core technology consists of two proprietary ADC platforms: Dolasynthen for creating homogeneous, cytotoxic ADCs with precise drug-to-antibody ratios, and Immunosynthen for developing STING-agonist ADCs designed to stimulate the innate immune system within the tumor microenvironment.